Clinical Trials Logo

Clinical Trial Summary

The aim of the present study is to investigate the effect of probiotic supplementation on GI related quality of life, through a randomised placebo-controlled clinical trial. Moreover, the invetigators wish to study CF microbiota and intestinal inflammation in the setting of probiotic supplementation and newly started treatment with a highly effective CF-specific treatment, elexacaftor-tezacaftor-ivacaftor (ETI). The proposed project has the potential to increase QoL and decrease GI morbidity in children with CF. If successful, the results of this study can contribute to alter the care of CF patients by including supplementation of probiotics in routine CF care. Morever, the study can provide much needed insights to GI microbiota and inflammation in pediatric CF patients.


Clinical Trial Description

The project targets pediatric patients with cystic fibrosis (CF), and has to work packages (WP). WP1 is an observational study, and WP2 is a randomised placebo-controlled clinical trial. The goal of the study is to investigate the effect of probiotics on pediatric CF patients' quality of life (QoL). Moreover the investigators wish to explore effects of both a highly effective CFTR modulator and probiotics on gut microbiota and intestinal inflammation. The primary question it aims to answer are: • Can probiotics improve GI related QoL in children with CF? Secondary aims are to: - Investigate GI microbiota and GI inflammation before and after commencement of the highly effective triple-combination elexacaftor-tezacaftor-ivacaftor (ETI) - Explore GI microbiota before and after treatment with probiotics vs. placebo - Study intestinal inflammation before and after treatment with probiotics vs. placebo - Examine body composition and its relation to lung function In WP1 participants will during routine examination before starting treatment with ETI be asked to deliver stool samples, and fill in QoL questionnaires. In WP2 participants will be randomized to intervention with probiotics or placebo, and the same parameters as in WP1 will also be collected. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06284577
Study type Interventional
Source Oslo University Hospital
Contact
Status Recruiting
Phase N/A
Start date January 2, 2024
Completion date July 1, 2027

See also
  Status Clinical Trial Phase
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Active, not recruiting NCT04602468 - Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Phase 4
Completed NCT06109675 - Nutritional Status Assessment of Pediatric Cystic Fibrosis Patients and Effect of Nutrition Education on Nutritional Status N/A
Active, not recruiting NCT04392544 - Intestinal Inflammation in CF Patients
Completed NCT04084041 - Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis N/A
Not yet recruiting NCT03292718 - Clinical Trial to Assess Influence of MyCyFAPP Use on GI Related QOL in Children With Cystic Fibrosis N/A
Not yet recruiting NCT05493137 - Physical Activity Levels of Parents of Children With Cystic Fibrosis- (PHACTS-CF)
Enrolling by invitation NCT06188988 - Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis
Recruiting NCT04174664 - Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
Completed NCT04138589 - Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
Completed NCT03579173 - Determinants of Early Cystic Fibrosis Lung Disease
Recruiting NCT05850351 - Virtual Reality Based Tele-Exercises on Exercise Capacity in Cystic Fibrosis N/A
Completed NCT04463628 - Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic
Completed NCT04835376 - Percussion Palm Cup: Safety and Usability in Infants and Children With Cystic Fibrosis N/A
Completed NCT04293926 - Heart Rate Variability in Children and Adolescents With Cystic Fibrosis N/A
Completed NCT04987567 - Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients N/A
Withdrawn NCT04415268 - Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis N/A
Not yet recruiting NCT06066723 - 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Terminated NCT03939065 - Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management N/A
Active, not recruiting NCT04613128 - The PROMISE Pediatric Study 6 to 11 Years Old